Advertisement

Neurological Sciences

, Volume 23, Issue 4, pp 145–151 | Cite as

Glutamic acid decarboxylase autoantibodies and neurological disorders

  • M. Vianello
  • B. Tavolato
  • B. Giometto
REVIEW

Abstract.

Glutamic acid decarboxylase (GAD) is the enzyme that catalyses the production of GABA, a major neurotransmitter of the central nervous system. Antibodies to GAD (GAD-Ab) were first recognised in a patient affected by stiff-person syndrome; subsequently they were reported in a large number of cases with type 1 diabetes. Recently GADAb have been described in a number of patients affected by chronic cerebellar ataxia, drug-resistant epilepsy and myoclonus. These cases usually harbour other autoantibodies or are affected by organ-specific autoimmune diseases. The role of GAD-Ab is still unclear; the lack of experimental models makes it difficult to investigate their potential pathogenetic role. However two mechanisms have been suggested: the reduction by GAD-Ab of GABA synthesis in nerve terminals or the interference with exocytosis of GABA.

Key words GAD autoantibodies Stiff-person syndrome Chronic cerebellar ataxia Epilepsy Polyglandular autoimmunity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Italia 2002

Authors and Affiliations

  • M. Vianello
    • 1
  • B. Tavolato
    • 1
  • B. Giometto
    • 1
  1. 1.Department of Neurology and Psychiatry Sciences, Second Clinic, University of Padua, Via Vendramini 7, I-35121 Padua, ItalyIT

Personalised recommendations